The Danaher Corporation, a prominent entity in the health care sector, recently disclosed changes in the beneficial ownership of its common stock through Form 4 filings on October 29, 2026. The company, headquartered in Washington, is renowned for its diverse portfolio, encompassing professional, medical, industrial, and commercial products and services across sectors such as test and measurement, environmental, life sciences, dental, and industrial technologies. Danaher is publicly traded on the New York Stock Exchange, with a market capitalization of approximately $163.18 billion as of October 29, 2026.
The filings revealed transactions by two key executives: Christopher Bouda, the Chief Accounting Officer, and Matthew McGrew, the Executive Vice-President. On October 28, 2026, Bouda engaged in multiple transactions involving the sale and acquisition of shares. Concurrently, McGrew sold a substantial block of shares and later purchased a significant number, resulting in a net increase in his holdings. Both executives exercised employee stock options on the same day, converting these options into shares at the prevailing market price. The shares acquired through these exercises were retained in their respective accounts.
The filings provided detailed information on the pricing of the sold shares and the exercise dates of the options. Notably, no new corporate actions or significant strategic developments were reported in these filings. As of the close of trading on October 29, 2026, Danaher’s stock was priced at $232.23, with a 52-week high of $242.80 and a low of $160.93. The company’s price-to-earnings ratio stood at 38.94, reflecting its market valuation relative to its earnings.
For further insights into Danaher’s offerings and corporate activities, stakeholders are encouraged to visit the company’s official website at www.danaher.com .
